Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN.

Adult Antineoplastic Agents / therapeutic use Humans Leukemia, Myeloid, Acute / diagnosis Mutation Neoplasm, Residual / diagnosis Nucleophosmin Prognosis Proto-Oncogene Proteins c-bcl-2 / genetics

Journal

Blood
ISSN: 1528-0020
Titre abrégé: Blood
Pays: United States
ID NLM: 7603509

Informations de publication

Date de publication:
22 09 2022
Historique:
received: 29 04 2022
accepted: 29 06 2022
pubmed: 8 7 2022
medline: 28 9 2022
entrez: 7 7 2022
Statut: ppublish

Résumé

The 2010 and 2017 editions of the European LeukemiaNet (ELN) recommendations for diagnosis and management of acute myeloid leukemia (AML) in adults are widely recognized among physicians and investigators. There have been major advances in our understanding of AML, including new knowledge about the molecular pathogenesis of AML, leading to an update of the disease classification, technological progress in genomic diagnostics and assessment of measurable residual disease, and the successful development of new therapeutic agents, such as FLT3, IDH1, IDH2, and BCL2 inhibitors. These advances have prompted this update that includes a revised ELN genetic risk classification, revised response criteria, and treatment recommendations.

Identifiants

DOI: 10.1182/blood.2022016867 PMID: 35797463
pubmed: 35797463
pii: S0006-4971(22)00887-4
doi: 10.1182/blood.2022016867
doi:

Substances chimiques

Antineoplastic Agents 0
Proto-Oncogene Proteins c-bcl-2 0
Nucleophosmin 117896-08-9

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

1345-1377

Commentaires et corrections

Type : CommentIn

Informations de copyright

© 2022 by The American Society of Hematology.

Auteurs

Hartmut Döhner (H)

Department of Internal Medicine III, Ulm University Hospital, Ulm, Germany.
ORCID: 0000-0003-2116-5536

Andrew H Wei (AH)

Department of Haematology, Peter MacCallum Cancer Centre, Royal Melbourne Hospital and University of Melbourne, Melbourne, Australia.
ORCID: 0000-0002-7514-3298

Frederick R Appelbaum (FR)

University of Washington and the Fred Hutchinson Cancer Research Center, Seattle, WA.

Charles Craddock (C)

Centre for Clinical Haematology, Queen Elizabeth Hospital, University of Birminham, Birmingham, UK.

Courtney D DiNardo (CD)

Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX.
ORCID: 0000-0001-9003-0390

Hervé Dombret (H)

Department of Hematology, Saint-Louis Institute for Research, Université de Paris, Hôpital Saint-Louis, Assistance Publique-Hôpitaux de Paris, Paris, France.

Benjamin L Ebert (BL)

Dana-Farber Cancer Institute, Boston, MA.
ORCID: 0000-0003-0197-5451

Pierre Fenaux (P)

Service d'Hématologie Séniors, Hôpital Saint-Louis, Assistance Publique-Hôpitaux de Paris, Paris, France.

Lucy A Godley (LA)

Section of Hematology/Oncology, Department of Medicine, The University of Chicago, Chicago, IL.

Robert P Hasserjian (RP)

Department of Pathology, Massachusetts General Hospital, Boston, MA.
ORCID: 0000-0002-7753-0697

Richard A Larson (RA)

Department of Medicine and Comprehensive Cancer Center, University of Chicago, Chicago, IL.
ORCID: 0000-0001-9168-3203

Ross L Levine (RL)

Human Oncology and Pathogenesis Program and Leukemia Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY.

Yasushi Miyazaki (Y)

Department of Hematology, Atomic Bomb Disease Institute, Nagasaki University, Nagasaki, Japan.

Dietger Niederwieser (D)

University of Leipzig, Leipzig, Germany.

Gert Ossenkoppele (G)

Department of Haematology, Amsterdam UMC, Location VU University Medical Center, Amsterdam, The Netherlands.

Christoph Röllig (C)

Department of Internal Medicine I, University Hospital Carl Gustav Carus TU Dresden, Dresden, Germany.

Jorge Sierra (J)

Hematology Department, Hospital Santa Creu i Sant Pau, Barcelona, Spain.
ORCID: 0000-0002-7966-0356

Eytan M Stein (EM)

Leukemia Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York.

Martin S Tallman (MS)

Leukemia Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York.

Hwei-Fang Tien (HF)

Division of Hematology, Department of Internal Medicine, National Taiwan University Hospital, Taipei, Taiwan.

Jianxiang Wang (J)

Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, China.
ORCID: 0000-0001-9437-9151

Agnieszka Wierzbowska (A)

Department of Hematology, Medical University of Lodz, Lodz, Poland; and.
ORCID: 0000-0001-7909-457X

Bob Löwenberg (B)

Department of Hematology, Erasmus University Medical Center Rotterdam and Erasmus MC Cancer Institute, Rotterdam, The Netherlands.
ORCID: 0000-0001-8982-5217

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female

Evaluation of Low-Value Services Across Major Medicare Advantage Insurers and Traditional Medicare.

Ciara Duggan, Adam L Beckman, Ishani Ganguli et al.
1.00
Humans United States Aged Cross-Sectional Studies Medicare Part C

Effectiveness of Virtual Yoga for Chronic Low Back Pain: A Randomized Clinical Trial.

Hallie Tankha, Devyn Gaskins, Amanda Shallcross et al.
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH

questionsmedicales.fr › Personnes › Tranches d'âge › Adulte › Diagnosis and management of AML in adults:...
questionsmedicales.fr › Actions chimiques et utilisations › Actions pharmacologiques › Utilisations thérapeutiques › Antinéoplasiques › Diagnosis and management of AML in adults:...
questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Primates › Haplorhini › Catarrhini › Hominidae › Humains › Diagnosis and management of AML in adults:...
questionsmedicales.fr › Tumeurs › Tumeurs par type histologique › Leucémies › Leucémie myéloïde › Leucémie aigüe myéloïde › Diagnosis and management of AML in adults:...
questionsmedicales.fr › Phénomènes génétiques › Variation génétique › Mutation › Diagnosis and management of AML in adults:...
questionsmedicales.fr › États, signes et symptômes pathologiques › Processus pathologiques › Processus néoplasiques › Maladie résiduelle › Diagnosis and management of AML in adults:...
questionsmedicales.fr › Acides aminés, peptides et protéines › Protéines › Protéines nucléaires › Nucléophosmine › Diagnosis and management of AML in adults:...
questionsmedicales.fr › Diagnostic › Pronostic › Diagnosis and management of AML in adults:...
questionsmedicales.fr › Acides aminés, peptides et protéines › Protéines › Protéines tumorales › Protéines oncogènes › Protéines proto-oncogènes › Protéines proto-oncogènes c-bcl-2 › Diagnosis and management of AML in adults:...